NEWS
GE HEALTHCARE INTRODUCES MIM SYMPHONY HDR PROSTATE FOR MRI GUIDANCE DURING PROCEDURES
GE HealthCare ’ s MIM Software , a global provider of medical imaging analysis and Artificial Intelligence ( AI ) solutions , is excited to introduce MIM Symphony HDR Prostate to support high dose-rate ( HDR ) brachytherapy .
This innovative solution aims to increase clinician confidence and help improve patient outcomes by providing direct tumour visualisation from magnetic resonance imaging ( MRI ) scans during live ultrasound procedures for HDR prostate treatments .
MIM Symphony HDR Prostate stands out in the market by correcting MRI orientation and offering MRI guidance during HDR prostate procedures .
HDR brachytherapy is a prostate cancer treatment that involves implanting radioactive sources into the prostate gland via needles . Typically , clinicians use computed tomography ( CT ) or ultrasound imaging for planning these procedures . Incorporating MRI into brachytherapy treatment planning can reduce toxicity to critical structures . However , the challenge of accurately aligning MRI contours with live ultrasound images has hindered the use of MRI in HDR treatments .
Dr Peter Rossi , MD , FABS , Chairman of the Board at the American Brachytherapy Society and Radiation Oncologist at Valley View Hospital , said : “ I often get the question , what is the best imaging modality for planning HDR prostate procedures , ultrasound or CT ? My response is always MRI . MRI guidance enables more confident , precise treatments and reduces toxicity to organs at risk . I ’ ve had the pleasure of providing my patients with precise treatments using MRI guidance in MIM Symphony HDR Prostate , and I look forward to other clinics having the same opportunity .”
REVELAI HEALTH AND ZIMMER BIOMET AGREE TO ADVANCE VALUE-BASED CARE AND HEALTH EQUITY THROUGH AI-POWERED TECHNOLOGY
Health and Zimmer Biomet Holdings , a global medical technology leader , has announced a multi-year comarketing agreement to commercialise GenAI-powered engagement solutions that advance value-based orthopaedic care and health equity . During the multi-year agreement , Zimmer Biomet will commercialise RevelAi Health ’ s patient care-management platform , care team dashboard for providers and any future products or services .
Péan MD , MS , CEO of RevelAi Health and an orthopaedic trauma surgeon at Duke University School of Medicine . “ Our AI-enabled asynchronous care model delivers personalised , timely , and effective patient care while reducing clinician burnout . Our collaboration with Zimmer Biomet is a significant step towards ensuring that every patient receives the care they deserve .”
RevelAi health is a software as a service ( SAAS ) health technology company that specialises in cutting-edge GenAI population health solutions . RevelAi Health ’ s clinician-validated large language model helps healthcare providers transition seamlessly to valuebased care , meeting essential CMS ( Centers for Medicare and Medicaid Services ) requirements , including Patient Reported Outcome measures and Social Drivers of Health ( SDOH ) Screening .
“ Leveraging generative AI to streamline clinical care workflows while addressing socio-demographic disparities is a unique opportunity to drive equitable value-based outcomes ,” said Christian
6 www . intelligenthealth . tech